Biologics Research Review, Issue 38 - Rheumatology focus

In this issue:

Subcutaneous anifrolumab for SLE
Fasinumab in patients with chronic low back pain
Tocilizumab for primary Sjögren syndrome
Tocilizumab for hand OA
Vision loss in giant cell arteritis treated with tocilizumab
Transcriptome study of TNF-inhibitor response in RA
Prediction of flare in RA patients tapering biologics
Tocilizumab monotherapy vs combination therapy in refractory giant cell arteritis
Adherence and persistence with adalimumab citrate-free and citrate formulations
Ixekizumab: patient-reported outcomes in non-radiographic axial SpA
Remission endpoints of secukinumab over 3 years in active AS
COVID-19 and biological agents for rheumatic diseases

Please login below to download this issue (PDF)

Subscribe